MA33945B1 - Procédés de fabrication d'un principe pharmaceutiquement actif - Google Patents
Procédés de fabrication d'un principe pharmaceutiquement actifInfo
- Publication number
- MA33945B1 MA33945B1 MA35092A MA35092A MA33945B1 MA 33945 B1 MA33945 B1 MA 33945B1 MA 35092 A MA35092 A MA 35092A MA 35092 A MA35092 A MA 35092A MA 33945 B1 MA33945 B1 MA 33945B1
- Authority
- MA
- Morocco
- Prior art keywords
- methods
- making effective
- effective pharmaceuticals
- pharmaceuticals
- making
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D209/16—Tryptamines
Abstract
La présente invention concerne des procédés de préparation d'un principe pharmaceutiquement actif et de ses sels pharmaceutiquement acceptables.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28953009P | 2009-12-23 | 2009-12-23 | |
PCT/DK2010/050348 WO2011076212A2 (fr) | 2009-12-23 | 2010-12-20 | Procédés de fabrication d'un principe pharmaceutiquement actif |
Publications (1)
Publication Number | Publication Date |
---|---|
MA33945B1 true MA33945B1 (fr) | 2013-01-02 |
Family
ID=43567689
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA35092A MA33945B1 (fr) | 2009-12-23 | 2010-12-20 | Procédés de fabrication d'un principe pharmaceutiquement actif |
Country Status (37)
Country | Link |
---|---|
US (3) | US8461353B2 (fr) |
EP (1) | EP2516394B1 (fr) |
JP (2) | JP5864435B2 (fr) |
KR (2) | KR101873182B1 (fr) |
CN (2) | CN102656146B (fr) |
AR (1) | AR079580A1 (fr) |
AU (1) | AU2010335659B2 (fr) |
BR (1) | BR112012015749A2 (fr) |
CA (1) | CA2785440C (fr) |
CL (1) | CL2012001725A1 (fr) |
CR (1) | CR20120316A (fr) |
CY (1) | CY1118032T1 (fr) |
DK (1) | DK2516394T3 (fr) |
DO (1) | DOP2012000170A (fr) |
EA (1) | EA021440B1 (fr) |
ES (1) | ES2575666T3 (fr) |
GE (1) | GEP20146078B (fr) |
HK (2) | HK1174921A1 (fr) |
HR (1) | HRP20160518T1 (fr) |
HU (1) | HUE028806T2 (fr) |
IL (2) | IL220329A (fr) |
MA (1) | MA33945B1 (fr) |
ME (1) | ME02401B (fr) |
MX (1) | MX2012007078A (fr) |
MY (1) | MY159251A (fr) |
NZ (2) | NZ600639A (fr) |
PL (1) | PL2516394T3 (fr) |
PT (1) | PT2516394E (fr) |
RS (1) | RS54820B1 (fr) |
SG (1) | SG181910A1 (fr) |
SI (1) | SI2516394T1 (fr) |
SM (1) | SMT201600166B (fr) |
TN (1) | TN2012000279A1 (fr) |
TW (1) | TW201139370A (fr) |
UA (1) | UA111584C2 (fr) |
WO (1) | WO2011076212A2 (fr) |
ZA (1) | ZA201305936B (fr) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201139370A (en) | 2009-12-23 | 2011-11-16 | Lundbeck & Co As H | Processes for the manufacture of a pharmaceutically active agent |
JO3459B1 (ar) | 2012-09-09 | 2020-07-05 | H Lundbeck As | تركيبات صيدلانية لعلاج مرض الزهايمر |
JO3639B1 (ar) * | 2014-07-04 | 2020-08-27 | H Lundbeck As | صورة متعددة الشكل جديدة لـ n-[2-(6-فلورو-1h-إندول-3-يل)إيثيل]-3-(2،2،3،3-تترا فلورو بروبوكسي)بنزيل أمين هيدروكلوريد |
CN104130174A (zh) * | 2014-07-30 | 2014-11-05 | 天津市斯芬克司药物研发有限公司 | 一种吲唑衍生物及其制备方法 |
CN105175307A (zh) * | 2014-11-18 | 2015-12-23 | 苏州晶云药物科技有限公司 | Lu AE58054的盐酸盐晶型A及其制备方法和用途 |
TW201630881A (zh) | 2014-12-12 | 2016-09-01 | H 朗德貝克公司 | 用於生產艾達魯吡啶之方法 |
CN104529865B (zh) * | 2014-12-12 | 2017-02-01 | 广东东阳光药业有限公司 | 苄胺类衍生物及其在药物上的应用 |
MA41148A (fr) * | 2014-12-12 | 2017-10-17 | H Lundbeck As | Procédé de fabrication d'idalopirdine |
CN108271369A (zh) * | 2015-10-23 | 2018-07-10 | 法尔玛赞公司 | 用于制备色胺及其衍生物的新工艺 |
JP2019513742A (ja) | 2016-04-08 | 2019-05-30 | ハー・ルンドベック・アクチエゼルスカベット | イミンの水素化によるイダロピルジンの製造方法 |
EP3333154A1 (fr) * | 2016-12-07 | 2018-06-13 | Sandoz Ag | Forme cristalline d'un antagoniste sélectif du récepteur 5-ht6 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3042685A (en) | 1962-07-03 | Process of making g-fluoro tryptamine | ||
GB846675A (en) | 1958-04-18 | 1960-08-31 | Lab Francais Chimiotherapie | Process for the production of a tryptamine derivative |
US4803218A (en) * | 1982-09-29 | 1989-02-07 | Mcneilab, Inc. | 3-aminoalkyl-1H-indole-5-urea and amide derivatives |
DE69416697T2 (de) | 1993-12-28 | 1999-09-09 | Rhone Poulenc Fibres | Verfahren zur katalytischer hydrogenierung von nitrilen zu aminen in anwesenheit eines dosierten raney nickel katalysators |
EP0737101B1 (fr) | 1993-12-28 | 1998-09-23 | RHODIA FIBER & RESIN INTERMEDIATES | Procede de preparation d'un catalyseur d'hydrogenation de nitriles en amines et application de ce catalyseur en hydrogenation |
US5869653A (en) | 1997-10-30 | 1999-02-09 | Air Products And Chemicals, Inc. | Hydrogenation of nitriles to produce amines |
KR20000069831A (ko) | 1997-10-31 | 2000-11-25 | 요트.게.아. 롤페즈 | 구성 신호에 대한 잡음 추가를 통한 엘피씨 원칙에 따라 인코딩된 음성의 오디오 표현을 위한 방법 및 장치 |
US6156694A (en) | 1998-11-05 | 2000-12-05 | E. I. Dupont De Nemours & Company | Raney cobalt catalyst and a process for hydrogenating organic compounds using said catalyst |
AU2002303094B2 (en) | 2001-03-29 | 2006-11-23 | Eli Lilly And Company | N-(2-arylethyl)benzylamines as antagonists of the 5-HT6 receptor |
US7084154B2 (en) * | 2003-02-11 | 2006-08-01 | Pharmacopeia Drug Disclovery, Inc. | 2-(aminomethyl) arylamide analgesics |
FR2866335B1 (fr) | 2004-02-13 | 2006-05-26 | Servier Lab | Nouveau procede de synthese de l'agomelatine |
JP2006169113A (ja) * | 2004-12-10 | 2006-06-29 | Dainippon Sumitomo Pharma Co Ltd | インドール類の合成方法および合成中間体 |
WO2007070796A1 (fr) * | 2005-12-15 | 2007-06-21 | Exelixis, Inc. | Derives d'azepinoindole en tant qu'agents pharmaceutiques |
EP2002834A1 (fr) * | 2007-06-13 | 2008-12-17 | Bayer Schering Pharma Aktiengesellschaft | Aryle/hétarylamides en tant que modulateurs du récepteur EP2 |
JO2704B1 (en) * | 2007-09-21 | 2013-03-03 | جانسين فارماسوتيكا ان في | Interference inhibition factors between MD2 and B53 |
EP2219646A4 (fr) | 2007-12-21 | 2010-12-22 | Univ Rochester | Procédé permettant de modifier la durée de vie d'organismes eucaryotes |
WO2010036362A1 (fr) * | 2008-09-26 | 2010-04-01 | Wyeth | Inhibiteurs des récepteurs nucléaires de 1,2,3,6-tétrahydroazépino[4,5-b]indole-5-carboxylate |
CN101531624A (zh) | 2009-04-08 | 2009-09-16 | 大连凯飞精细化工有限公司 | 6-氟吲哚-3-乙腈的合成方法 |
TW201139370A (en) | 2009-12-23 | 2011-11-16 | Lundbeck & Co As H | Processes for the manufacture of a pharmaceutically active agent |
-
2010
- 2010-12-16 TW TW099144129A patent/TW201139370A/zh unknown
- 2010-12-20 NZ NZ600639A patent/NZ600639A/en not_active IP Right Cessation
- 2010-12-20 EA EA201290552A patent/EA021440B1/ru not_active IP Right Cessation
- 2010-12-20 SG SG2012046793A patent/SG181910A1/en unknown
- 2010-12-20 CA CA2785440A patent/CA2785440C/fr not_active Expired - Fee Related
- 2010-12-20 JP JP2012545093A patent/JP5864435B2/ja not_active Expired - Fee Related
- 2010-12-20 SI SI201031191A patent/SI2516394T1/sl unknown
- 2010-12-20 CN CN201080058864.9A patent/CN102656146B/zh not_active Expired - Fee Related
- 2010-12-20 ME MEP-2016-105A patent/ME02401B/fr unknown
- 2010-12-20 NZ NZ625798A patent/NZ625798A/en not_active IP Right Cessation
- 2010-12-20 PT PT108032228T patent/PT2516394E/pt unknown
- 2010-12-20 GE GEAP201012807A patent/GEP20146078B/en unknown
- 2010-12-20 KR KR1020177031907A patent/KR101873182B1/ko active IP Right Grant
- 2010-12-20 BR BR112012015749A patent/BR112012015749A2/pt active Search and Examination
- 2010-12-20 EP EP10803222.8A patent/EP2516394B1/fr active Active
- 2010-12-20 US US12/972,559 patent/US8461353B2/en not_active Expired - Fee Related
- 2010-12-20 MY MYPI2012002675A patent/MY159251A/en unknown
- 2010-12-20 RS RS20160382A patent/RS54820B1/sr unknown
- 2010-12-20 AU AU2010335659A patent/AU2010335659B2/en not_active Ceased
- 2010-12-20 HU HUE10803222A patent/HUE028806T2/en unknown
- 2010-12-20 MX MX2012007078A patent/MX2012007078A/es active IP Right Grant
- 2010-12-20 WO PCT/DK2010/050348 patent/WO2011076212A2/fr active Application Filing
- 2010-12-20 MA MA35092A patent/MA33945B1/fr unknown
- 2010-12-20 ES ES10803222.8T patent/ES2575666T3/es active Active
- 2010-12-20 PL PL10803222.8T patent/PL2516394T3/pl unknown
- 2010-12-20 UA UAA201207977A patent/UA111584C2/uk unknown
- 2010-12-20 DK DK10803222.8T patent/DK2516394T3/en active
- 2010-12-20 KR KR1020127016217A patent/KR101796330B1/ko active IP Right Grant
- 2010-12-20 CN CN201410004542.6A patent/CN103694161B/zh not_active Expired - Fee Related
- 2010-12-21 AR ARP100104826A patent/AR079580A1/es active IP Right Grant
-
2012
- 2012-05-31 TN TNP2012000279A patent/TN2012000279A1/en unknown
- 2012-06-12 IL IL220329A patent/IL220329A/en not_active IP Right Cessation
- 2012-06-12 CR CR20120316A patent/CR20120316A/es unknown
- 2012-06-18 DO DO2012000170A patent/DOP2012000170A/es unknown
- 2012-06-22 CL CL2012001725A patent/CL2012001725A1/es unknown
-
2013
- 2013-02-25 HK HK13102334.6A patent/HK1174921A1/xx not_active IP Right Cessation
- 2013-05-02 US US13/875,623 patent/US8901318B2/en not_active Expired - Fee Related
- 2013-08-07 ZA ZA2013/05936A patent/ZA201305936B/en unknown
-
2014
- 2014-02-25 IL IL231141A patent/IL231141A/en not_active IP Right Cessation
- 2014-09-26 HK HK14109681.9A patent/HK1196352A1/xx not_active IP Right Cessation
- 2014-11-25 US US14/553,029 patent/US9382205B2/en active Active
-
2015
- 2015-12-24 JP JP2015251874A patent/JP6195605B2/ja not_active Expired - Fee Related
-
2016
- 2016-05-16 HR HRP20160518TT patent/HRP20160518T1/hr unknown
- 2016-06-02 CY CY20161100488T patent/CY1118032T1/el unknown
- 2016-06-10 SM SM201600166T patent/SMT201600166B/it unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA33945B1 (fr) | Procédés de fabrication d'un principe pharmaceutiquement actif | |
EA201200763A1 (ru) | Замещенные производные карбамоилметиламиноуксусной кислоты в качестве новых ингибиторов nep | |
MA38050A1 (fr) | Inhibiteurs de gdf-8 | |
UA105229C2 (uk) | Фармацевтичний склад | |
MA37405A1 (fr) | Composés hétérocyclyle | |
MX2011012627A (es) | Derivados aminobutiricos sustituidos como inhibidores de nepralisina. | |
EA200800147A1 (ru) | Способ получения олмесартан медоксомила | |
EA201390723A1 (ru) | Аминозамещенные производные бисфенилпентановой кислоты в качестве ингибиторов nep | |
EA201170434A1 (ru) | Макроциклические ингибиторы сериновых протеаз гепатита с | |
GEP20146146B (en) | Pyrrolopyrimidine compounds as inhibitors of cdk4/6 | |
MX2011012628A (es) | Derivados amino-propionicos sustituidos como inhibidores de neprilisina. | |
MA30725B1 (fr) | Administration d'inhibiteurs de la dipeptidyl peptidase | |
EA201290191A1 (ru) | N1-ПИРАЗОЛОСПИРОКЕТОНОВЫЕ ИНГИБИТОРЫ АЦЕТИЛ-KoA-КАРБОКСИЛАЗЫ | |
PE20121337A1 (es) | Forma cristalina y amorfa de hemitartrato de genz 112638 como inhibidor de glucosilceramida sintasa | |
JO3577B1 (ar) | صيغ صيدلانية تشمل مشتقات 1-(بيتا-d- غلوكوبيرانوسيل) -2-ثينيل ميثيل بنزين كمثبطات sglt | |
UA97348C2 (en) | HETEROCYCLIC NF-kB INHIBITORS | |
MX2011011733A (es) | Inhiibidores de dihidroorotato deshidrogenasa como compuestos virostaticos. | |
UA96575C2 (en) | Process for the preparation of olmesartan medoxomil | |
UA101091C2 (ru) | Способ синтеза ивабрадина и его аддитивных солей с фармацевтически приемлемой кислотой | |
IN2012DN02502A (fr) | ||
MA32290B1 (fr) | Nouvelle classe de spiro pipéridines pour le traitement de maladies neurodégénératives | |
MA35188B1 (fr) | Tétrahydroquinolines à fusion cycloalkyle en tant que modulateurs de l'activité du récepteur crth2 | |
MY161749A (en) | Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use | |
MX2010010455A (es) | Formas solidas de un compuesto fosfoindol anti-vih. | |
MY179041A (en) | Crystalline forms of a 3-carboxypropyl-aminotetralin compound |